AdJane

In the world of vaccines, we are revolutionizing the landscape with our innovative adjuvant technology. Our disruptive adjuvant products boost the potential and efficacy of vaccines, addressing critical healthcare challenges by enhancing the immune response. AdJane aims to reshape how vaccines are developed and delivered, providing enhanced protection against various diseases for people around the world. Our proprietary Ada-24 adjuvant is based on and leverages the features of Outer Membrane Vesicles (OMVs), derived from gram-negative bacteria and further detoxified, resulting in a safe adjuvant already tested in humans. These nanoparticles are a powerful tool in enhancing the immune response due to their versatile and adaptable nature. Various studies have shown that the inclusion of our proprietary Ada-24 adjuvant elicits a broad immune response, outperforming conventional adjuvants.